Clostridium vaccine aids in preventing clostridial diseases including botulism, tetanus, and gas gangrene. The vaccines enhance immunity against clostridium bacteria and offer protection from severe illnesses. The global Clostridium vaccine market is driven by the rising cases of tetanus and increasing awareness regarding clostridial infections. The global Clostridium Vaccine Market is estimated to be valued at US$ 2.3 Bn in 2023 and is expected to exhibit a CAGR of 5.9% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
The increasing prevalence of clostridium diseases is one of the major factors fueling the growth of the global Clostridium vaccine market. As per World Health Organization (WHO), every year around 59,000 people die of tetanus across the globe. Most tetanus cases now occur in developing nations where vaccination coverage is low. Higher susceptibility of newborns to tetanus infection is another factor driving the demand for clostridium vaccines globally. Development of new and advanced clostridium vaccines incorporating innovative drug delivery technology and formulation is expected to present lucrative growth opportunities for market players over the forecast period.
Segment Analysis
The global Clostridium vaccine market is segmented on the basis of vaccine type and end user. Based on vaccine type, the market has been segmented into Pentavalent Clostridium vaccine and Heptavalent Clostridium vaccine. The pentavalent Clostridium vaccine segment is expected to dominate the market owing to its high effectiveness against five types of clostridium infection.
Key Takeaways
The Global Clostridium Vaccine Market Growth is expected to witness high during the forecast period of 2023 to 2030, expanding at a CAGR of 5.9%.
Regional analysis: North America is expected to be the fastest growing as well as the dominating regional market throughout the forecast period. Presence of major key players, increasing healthcare expenditure, and growing awareness regarding clostridium infections are some factors driving the growth of the Clostridium vaccine market in the region.
Key players: Key players operating in the Clostridium vaccine market are Novartis AG (Switzerland), Biogen Inc. (US), Gilead Sciences, Inc. (US), Bristol-Myers Squibb (US), Alnylam Pharmaceuticals, Inc. (US), and Sarepta Therapeutics, Inc. (US) among others. Novartis AG is expected to dominate the market owing to its strong brand presence and wide product portfolio of Clostridium vaccines.
Explore more information on this topic, Please visit -
https://www.insightprobing.com/clostridium-vaccine-market-share-and-demand-analysis/
Comments
Post a Comment